Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 3970601, 7 pages
https://doi.org/10.1155/2017/3970601
Research Article

Efficacy of Topical Compound Danxiong Granules for Treatment of Dermatologic Toxicities Induced by Targeted Anticancer Therapy: A Randomized, Double-Blind, Placebo-Controlled Trial

1Department of Traditional Chinese Medicine, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
3Department of Hepatobiliary Surgery, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
4Department of Cancer Epidemiology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
5Department of Urology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
6Emergency Department, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
7Department of Pharmacy, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Correspondence should be addressed to Aiping Tian; moc.621@naitgnipia

Received 15 March 2017; Revised 23 June 2017; Accepted 2 July 2017; Published 6 August 2017

Academic Editor: Jenny M. Wilkinson

Copyright © 2017 Aiping Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Yasui and K. Imai, “Novel molecular-targeted therapeutics for the treatment of cancer,” Anti-Cancer Agents in Medicinal Chemistry, vol. 8, no. 5, pp. 470–480, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. G. K. Dy and A. A. Adjei, “Understanding, recognizing, and managing toxicities of targeted anticancer therapies,” A Cancer Journal for Clinicians, vol. 63, no. 4, pp. 249–279, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Ulrich, J. T. Hartmann, W. Dörr, and S. Ugurel, “Skin toxicity of anti-cancer therapy,” JDDG - Journal of the German Society of Dermatology, vol. 6, no. 11, pp. 959–977, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Robert, V. Sibaud, C. Mateus, and B. S. Cherpelis, “Advances in the management of cutaneous toxicities of targeted therapies,” Seminars in Oncology, vol. 39, no. 2, pp. 227–240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. C. Rosen, E. C. Case, S. W. Dusza et al., “Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic,” American Journal of Clinical Dermatology, vol. 14, no. 4, pp. 327–333, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Borovicka, C. Calahan, M. Gandhi et al., “Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents,” Archives of Dermatology, vol. 147, no. 12, pp. 1403–1409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. T. J. Lynch Jr., E. S. Kim, B. Eaby, J. Garey, D. P. West, and M. E. Lacouture, “Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management,” Oncologist, vol. 12, no. 5, pp. 610–621, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Gutzmer, A. Wollenberg, S. Ugurel, B. Homey, A. Ganser, and A. Kapp, “Cutaneous side effects of new antitumor drugs: clinical features and management,” Deutsches Arzteblatt International, vol. 109, no. 8, pp. 133–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Peuvrel and B. Dréno, “Dermatological toxicity associated with targeted therapies in cancer: optimal management,” American Journal of Clinical Dermatology, vol. 15, no. 5, pp. 425–444, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Koo and S. Arain, “Traditional chinese medicine for the treatment of dermatologic disorders,” Archives of Dermatology, vol. 134, no. 11, pp. 1388–1393, 1998. View at Google Scholar · View at Scopus
  11. J. Koo and R. Desai, “Traditional Chinese medicine in dermatology,” Dermatologic Therapy, vol. 16, no. 2, pp. 98–105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Ye, Y. Jia, K. Ji et al., “Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis (Review),” Oncology Letters, vol. 10, no. 3, pp. 1240–1250, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Nie, C. Zhao, L. I. Deng et al., “Efficacy of traditional Chinese medicine in treating cancer,” Biomedical Reports, vol. 4, pp. 3–14, 2016. View at Google Scholar
  14. M. Y. Hu and P. F. Chen, “Research progress in therapy of EGFRI-associated rash by traditional chinese medicine,” Journal of Jiangxi University of Traditional Chinese Medicine, vol. 28, pp. 122–124, 2016. View at Google Scholar
  15. “National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events v3.0 (CTCAE),” http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
  16. H. T. Eng and A. Chan, “Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors,” Annals of Pharmacotherapy, vol. 43, no. 10, pp. 1658–1666, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. H. J. Guo and Z. J. Wang, “Traditional Chinese medicine intervention on skin toxicity induced by epidermal growth factor receptor inhibitor,” Journal of Traditional Chinese Medicine, vol. 36, pp. 570–573, 2014. View at Google Scholar
  18. Y. Zhang, LC. Deng, and WS. Shen, “Antipruritic prescription treatment for acneiform eruption caused by targeted anticancer agents,” Zhejiang Journal of Integrated Traditional Chinese, vol. 19, pp. 371-372, 2009. View at Google Scholar
  19. H. Y. Wang, C. Zou, H. J. Cui, W. Wang, S. C. Jiao, and J. L. Li, “EGFRIs-related rash treated with external Chinese medicinal with actions of clearing heat and draining dampness in 120 cases,” Journal of Beijing University of Traditional Chinese Medicine, vol. 20, pp. 14–17, 2013. View at Google Scholar
  20. Y. H. Zhang, Y. Shen, L. Long, J. Yang, and T. Sun, “linical observation of treating rash induced by lung cancer targeted drug with Yangfei Xiaozhen Formula,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 31, pp. 100–103, 2016. View at Google Scholar